What causes pgd

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 4, 2026

Quick Answer: PGD, or paroxysmal nocturnal hemoglobinuria, is a rare acquired blood disorder that arises from a genetic mutation in a small number of a person's blood stem cells. This mutation leads to the production of abnormal blood cells that are more susceptible to destruction by the body's own immune system.

Key Facts

PGD is caused by a somatic mutation in the PIGA gene.
This mutation occurs in hematopoietic stem cells, which produce all blood cells.
The mutation leads to a deficiency in GPI-anchored proteins on the surface of blood cells.
This deficiency makes red blood cells particularly vulnerable to complement-mediated lysis.
PGD is an acquired condition, not inherited, meaning it develops during a person's lifetime.

What is Paroxysmal Nocturnal Hemoglobinuria (PGD)?

Paroxysmal nocturnal hemoglobinuria (PGD), often referred to as PNH, is a rare, chronic, and life-threatening blood disorder. It is characterized by the destruction of red blood cells (hemolysis), blood clots (thrombosis), and impaired bone marrow function. The 'paroxysmal nocturnal' aspect of its name refers to the historical observation that some patients experienced darker urine upon waking in the morning due to the presence of hemoglobin from destroyed red blood cells, though this is not a universal or constant symptom.

The Genetic Basis of PGD

The root cause of PGD lies in a specific genetic mutation. It is not an inherited disease in the traditional sense; rather, it is an acquired condition that develops due to a mutation in a single hematopoietic stem cell (HSC) within the bone marrow. HSCs are the progenitor cells responsible for generating all types of blood cells, including red blood cells, white blood cells, and platelets.

The mutation occurs in the PIGA gene, located on the X chromosome. The PIGA gene provides instructions for making an enzyme that is essential for attaching a specific type of protein, known as a glycosylphosphatidylinositol (GPI) anchor, to the surface of cells. Many crucial proteins, particularly those involved in regulating the immune system and preventing blood clot formation, are attached to the cell surface via these GPI anchors.

How the PIGA Mutation Leads to PGD Symptoms

When the PIGA gene in an HSC is mutated, the resulting cell and all its progeny (daughter cells) are unable to produce functional GPI anchors. This leads to a deficiency or complete absence of GPI-anchored proteins on the surface of the blood cells derived from that mutated stem cell.

The most critical consequence of this deficiency is observed in red blood cells. Normally, the surface of red blood cells is protected from the body's complement system – a part of the immune system that helps fight infections but can also damage cells. Several complement-regulatory proteins, such as CD55 and CD59, are GPI-anchored. In PGD, the absence of these protective proteins leaves red blood cells vulnerable to attack by the complement system. This results in the premature destruction of red blood cells, a process known as intravascular hemolysis.

Consequences of Hemolysis

The chronic destruction of red blood cells leads to several complications:

Anemia: The most common symptom of PGD is anemia, caused by the loss of red blood cells. Symptoms of anemia include fatigue, shortness of breath, paleness, and weakness.
Hemoglobinuria: As red blood cells are destroyed within blood vessels, their contents, including hemoglobin, are released into the bloodstream. Hemoglobin is then filtered by the kidneys and can appear in the urine, causing it to turn dark red or brown, especially noticeable in the morning.
Thrombosis: PGD is strongly associated with an increased risk of blood clots (thrombosis). The exact mechanisms are complex but involve the release of certain substances from damaged blood cells and a reduction in the activity of complement inhibitors that normally prevent clotting. These clots can occur in veins or arteries and can affect various organs, including the brain, lungs, and abdomen, leading to potentially life-threatening events like stroke or pulmonary embolism.
Bone Marrow Failure: Over time, the mutated clone of stem cells can expand, sometimes outcompeting healthy stem cells. This can lead to impaired production of all blood cell types, contributing to pancytopenia (low levels of red blood cells, white blood cells, and platelets) and increasing susceptibility to infections and bleeding.
Smooth Muscle Dystonia: Some patients experience pain in the abdomen, back, or chest, which can be related to smooth muscle spasms triggered by nitric oxide deficiency, a consequence of hemoglobin scavenging nitric oxide from the blood.

Diagnosis and Treatment

Diagnosis of PGD is typically made through a blood test called flow cytometry, which can detect the absence of GPI-anchored proteins on blood cells. Treatment aims to manage symptoms, prevent complications, and, in some cases, address the underlying clonal expansion.

Modern treatments focus on inhibiting the complement system to prevent red blood cell destruction. Medications like eculizumab and ravulizumab are highly effective in blocking the C5 component of the complement cascade, thereby reducing hemolysis and thrombotic events. Bone marrow transplantation remains a potential curative option but is associated with significant risks.

Prognosis

Without treatment, PGD can have a poor prognosis, with a significant risk of mortality due to thrombosis, infection, or bleeding. However, with the advent of targeted therapies that effectively control hemolysis and reduce thrombosis, the outlook for patients with PGD has dramatically improved, allowing for a better quality of life and longer survival rates.